MCNAB JAMES R

Average Profitability
15.48%
Insider Buys Quantity
12
Insider Buys Sum
$898,560.16
Insider Sells Quantity
29
Insider Sells Sum
$4.24M

Insider Activity of MCNAB JAMES R

The largest purchase of all time was on 2013-08-16 and amounted to 50000 shares of Curis, Inc. for $200,000.

The largest sale of all time was on 2012-06-18 and amounted to 150000 shares of Curis, Inc. for $712,500.

Biography of MCNAB JAMES R

No biography is available at this moment.

2018-09-21PurchaseTitan Pharmaceuticals, Inc.
TTNP
director
200,000
1.0535%
$0.25$50,000+10.23%
2017-05-05SaleCuris, Inc.
CRIS
director
16,176
0.0113%
$1.90$30,721-20.63%
2017-05-04SaleCuris, Inc.
CRIS
director
30,100
0.0213%
$1.97$59,159-22.42%
2017-05-03SaleCuris, Inc.
CRIS
director
30,000
0.0213%
$2.18$65,544-29.21%
2017-05-02SaleCuris, Inc.
CRIS
director
35,646
0.0249%
$2.31$82,314-33.48%
2017-05-01SaleCuris, Inc.
CRIS
director
38,113
0.0266%
$2.38$90,709-34.81%
2017-04-28SaleCuris, Inc.
CRIS
director
42,949
0.0302%
$2.45$105,015-35.54%
2017-04-27SaleCuris, Inc.
CRIS
director
37,202
0.0264%
$2.57$95,624-38.1%
2017-04-26SaleCuris, Inc.
CRIS
director
52,552
0.0362%
$2.65$139,089-41.39%
2017-04-25SaleCuris, Inc.
CRIS
director
56,940
0.0395%
$2.60$148,306-39.85%
2017-04-24SaleCuris, Inc.
CRIS
director
42,076
0.0294%
$2.56$107,862-38.43%
2017-04-21SaleCuris, Inc.
CRIS
director
45,705
0.0324%
$2.58$117,841-37.94%
2017-04-20SaleCuris, Inc.
CRIS
director
22,541
0.0156%
$2.66$59,979-41.2%
2016-05-31PurchaseTitan Pharmaceuticals, Inc.
TTNP
director
20,000
0.0975%
$7.03$140,600-36.7%
2016-01-13PurchaseTitan Pharmaceuticals, Inc.
TTNP
director
16,363
0.0756%
$3.16$51,707+46.63%
2013-08-16SaleCuris, Inc.
CRIS
director
50,000
0.062%
$4.00$200,000-27.62%
2013-08-16PurchaseCuris, Inc.
CRIS
director
50,000
0.062%
$4.00$200,000-27.62%
2012-06-19SaleCuris, Inc.
CRIS
director
139,000
0.1736%
$4.76$661,640-25.41%
2012-06-18SaleCuris, Inc.
CRIS
director
150,000
0.1893%
$4.75$712,500-24.16%
2012-06-15SaleCuris, Inc.
CRIS
director
11,000
0.0139%
$4.73$52,030-23.79%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.